Assessment of Rational Use of Omeprazole According to the Clinical Practice Guideline for Prophylaxis of NSAID-associated Gastrointestinal Ulcers in a Community Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To study the rational use and expenditures of omeprazole for preventing gastrointestinal ulcers from the use of non-steroidal anti-inflammatory drugs (NSAIDs) in a community hospital. Methods: This retrospective study was conducted in patients aged 20 years and older with the prescription on oral omeprazole with NSAIDs who received outpatient care in the Hospital from October 1, 2017 to September 30, 2020. The study assessed the rational use of omeprazole use for preventing of NSAID-associated gastrointestinal ulcers according to the guidelines of the American College of Gastroenterology (ACG). Results: There were 29,992 prescriptions of omeprazole for preventing NSAID- associated gastrointestinal ulcers, accounting for 2,876,489 baht on the expenditure of omeprazole or 95.91 baht per prescription. The assessment revealed that the irrational use was found in 9,011 prescriptions (30.04%), accounting for 759,198 baht or 25.31 baht per prescription. Conclusion: Rate of irrational use of omeprazole for preventing NSAID- associated gastrointestinal ulcers within the Hospital was 30.04% with the cost per prescription at 25.31 baht for omeprazole per prescription. The Hospitals should develop a guideline for rational drug use to achieve cost-effectiveness and maximize the benefit to the patient.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
World Health Organization. Promoting rational use of medicines [online]. 2022 [cited Mar 1, 2022]. Availa- ble from: www.who.int/activities/promoting-rational-use-of-medicines.
Chankunapars P, Boonyarit P, Srisuphan V, Leung ruangrong P, Prapaso N. Service plan: Rational drug use. Nonthaburi: Ministry of Public Health; 2016.
Shayakul C, Pisonthi C, Wananukul W, Bunupuradah P, Kanjanarat P, Kittiyot Y, et al, editors. Rational drug use hospital manual. Nonthaburi: The Agricultural Cooperative Federation; 2015.
Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001; 52: 185–92.
Hunt R, Lazebnik LB, Marakhouski YC, Manuc M, GN R, Aye KS, et al. International consensus on guiding recommendations for management of patients with nonsteroidal anti-inflammatory drugs induced gastropathy-icon-g. Euroasian J Hepatogas troenterol 2018; 8: 148-60.
Varavithya V, Tirapat C, Rojpibulstit P, Poovichaya sumlit P, Prasert V, Vatcharavongvan P. Potentially inappropriate medication use and the hospitalization rate among Thai elderly patients: a retrospective cohort study. Eur J Clin Pharmacol 2022; 78: 1-28.
Chia CT, Lim WP, Vu CK. Inappropriate use of proton pump inhibitors in a local setting. Singapore Med J 2014; 55: 363-6.
Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm 2020; 42: 174-83.
Chariyawet P, Dilokthornsakul P. Omeprazole over use and is financial loss in a community hospital. Thai Journal of Pharmacy Practice 2018; 10: 437-48.
Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
World Health Organization. ICD-10. International statistical classification of diseases and related health problems 10th revision (ICD-10) [online]. 2019 [cited Oct 1, 2021]. Available from: icd.who.int/brow se10/2019/en.
Omeprazole. In: DRUGDEX [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2021 [cited Oct 1, 2021]. Available from: www.micro medexsolutions.com.
Khan MA, Howden CW. The role of proton pump inhibitors in the management of upper gastrointesti- nal disorders. Gastroenterol Hepatol 2018;14:169-75
Thai Neurogastroenterology and Motility Society. Thailand GERD guideline 2020. Bangkok: Prinable; 2020.
Gastroenterological Association of Thailand. Thai land consensus on Helicobactor pylori management 2015. Bangkok: Concept Medicus; 2016.
Pittayanon R, Leelakusolvong S, Vilaichone RK, Roj borwonwitaya J, Treeprasertsuk S, Mairiang P, et al. Thailand dyspepsia guidelines: 2018. Neurogastroen terol Motil 2019; 25: 15-26.
Doungngern T, Ngorsuraches S. Efficacy and safety of proton pump inhibitors. Nonthaburi: Akson Gra- phic and Design; 2012.
Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013; 15(Suppl 3): S5.
Strategy and Planning Division Ministry of Public Health. Key performance indicator 2021 [online]. 2021 [cited Oct 10, 2021]. Available from: bps.mop h.go.th/new_bps/kpitemplate2564.
Kerkoon P. The evaluation of prescribing omepra zole in khlongluamg hospital. The Government Pharmaceutical Organization 2020; 46: 17-22.
Chutimanukul P, Wannathong P. Review of omepra zole prescribing in Angthong hospital. Thai Journal of Clinical Pharmacy 2020; 26(2): 1-12.
Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res 2018; 14: 361-74.
